Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Lantern Pharma Inc.

Get SEC filing alerts via email and in your feed for Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

About Lantern Pharma Inc.

Lantern Pharma Inc. is an AI-driven biopharmaceutical company focused on developing targeted cancer therapies. Its proprietary RADR platform analyzes vast genomic and clinical data to identify and rescue promising drug candidates, including small molecules and antibody-drug conjugates. The company targets oncology markets with personalized, biomarker-driven treatments, leveraging data science to accelerate drug discovery, reduce costs, and improve patient outcomes in solid tumors and blood cancers.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Lantern Pharma Inc.

1
1
Lantern Pharma Inc. Lantern Pharma Reports $3.33 Million Net Loss in Q1 2026, Seeks Additional Funding

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Lantern Pharma Inc. Lantern Pharma Reports $17.12 Million Net Loss and Decreased R&D Expenses for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Lantern Pharma Inc. Lantern Pharma Reports Q3 2025 Financial Results with $4.18 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Lantern Pharma Inc. Lantern Pharma Reports Q2 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Lantern Pharma Inc. Lantern Pharma Reports Q1 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Lantern Pharma Inc. Lantern Pharma Reports $20.78 Million Net Loss for 2024, Driven by Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Lantern Pharma Inc. Lantern Pharma Reports Significant Decline in Total Assets and Net Losses Amid Rising Operating Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments